Correction: Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment

Oncogene. 2023 May;42(18):1508. doi: 10.1038/s41388-023-02629-2.

Dotan Moskovich^{1

2}, Yael Finkelshtein^{1

2}, Adi Alfandari^{1

2}, Amit Rosemarin^{1

2}, Tzuri Lifschytz³, Avivit Weisz⁴, Santanu Mondal⁵, Harinarayana Ungati⁵, Aviva Katzav⁴, Debora Kidron^{4

6}, Govindasamy Mugesh⁵, Martin Ellis^{1

6}, Bernard Lerer³, Osnat Ashur-Fabian^{7

8}

¹ Translational Oncology Laboratory, Hematology Institute and Blood Bank, Meir Medical Center, Kfar-Saba, Israel.
² Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
³ Biological Psychiatry Laboratory Hadassah - Hebrew University Medical Center, Jerusalem, Israel.
⁴ Department of Pathology, Meir Medical Center, Kfar Saba, Israel.
⁵ Department of Inorganic and Physical Chemistry, Indian Institute of Science, Bangalore, India.
⁶ Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
⁷ Translational Oncology Laboratory, Hematology Institute and Blood Bank, Meir Medical Center, Kfar-Saba, Israel. osnataf@gmail.com.
⁸ Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. osnataf@gmail.com.

No abstract available

Publication types